ARTICLE

The genetic architecture of Plakophilin 2 cardiomyopathy

Annika M. Dries1, Anna Kirillova3, Chloe M. Reuter1, John Garcia2, Hana Zouk3,4, Megan Hawley3,4, Brittney Murray5, Crystal Tichnell5, Kalliopi Pilichou5, Alexandros Protonotarios7, Argelia Medeiros-Domingo6, Melissa A. Kelly9, Christopher M. Haggerty9,20 and Marina Cerrone14, Luisa Mestroni15,20 Matthew R. G. Taylor15, Gianfranco Sinagra16, Marco Merlo16, Ardan M. Saguner17, Perry M. Elliott7, Kalliopi Pilichou6, Alexandros Protonotarios7, Argelia Medeiros-Domingo8, Melissa A. Kelly9, Aris Baras10, Jodie Ingles11, Christopher Semsarian12, Barbara Bauce6, Rudy Celeghin6, Cristina Basso6, Jan D. H. Jongbloed13, Robert L. Nussbaum2, Birgit Funke3,4, Pancreatic Cancer Research Institute, Stanford University, Stanford, CA, USA. 2Invitae, Inc, San Francisco, CA, USA. 3Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, Cambridge, MA, USA. 4Dept. Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 5Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 6Dept. of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua, Italy. 7Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK. 8SwissDNA-lsisi-Cardiogenics, Dübendorf Switzerland, Zurich, Switzerland. 9Geisinger, Danville, PA, USA. 10Regenier Genetics Center, Tarrytown, NY, USA. 11Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. 12Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, University of Sydney, Sydney, Australia. 13University of Groningen Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands. 14Leon H. Charney Division of Cardiology, NYU School of Medicine, New York, NY, USA. 15University of Colorado Anschutz Medical Campus, Aurora, CO, US. 16Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste, Italy. 17Department of Cardiology, University Heart Center, University Hospital, Zurich, Switzerland. 18Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands. 19Netherlands Heart Institute, Utrecht, the Netherlands. 20These authors contributed equally: Cynthia A. James, Christopher M. Haggerty, Victoria N. Parikh. *A list of members and their affiliations appears in the Supplementary Information. 21email: vparikh@stanford.edu

INTRODUCTION

The yield of genetic testing in inherited cardiovascular disease relies on identification of disease-causing genes and the ability to distinguish pathogenic from benign variation therein. Efforts to define the genetic architecture of inherited cardiomyopathies have yielded significant improvement in our understanding of their most common genetic etiologies and population rarity. However, comprehensive position-specific variant pathogenicity assessment remains elusive. Recent efforts have characterized regional patterns in variant-disease association in genes including TTN, MYH7, DSP, and most recently MYBPC3. We showed that agnostic regional comparison of variants found in disease-associated cohorts versus the general population confirmed known functional domains and novel areas of interest in the gene RBM20. Here, we refine and apply this heuristic along with a gene-wide analysis to investigate the genetic architecture of a well-known cause of arhythmogenic cardiomyopathy (ACM): Plakophilin 2 (PKP2).

PKP2 is the most common gene associated with ACM, specifically its right dominant subform, arhythmogenic right ventricular cardiomyopathy (ARVC). The PKP2 protein is part of the desmosome, critical for cell–cell adhesion, and has several known functional domains including the HR2 domain at its N-terminus as well as eight Armadillo repeats, thought to be involved in protein interactions. PKP2 cardiomyopathy, like many genetic causes of cardiomyopathy, is inherited in an autosomal dominant fashion, and is thought to predominantly affect the right ventricle, therefore being specifically associated with ARVC. Prior observations in ARVC have suggested that loss of function PKP2 variants explain a significant etiologic fraction (EF) of this disease.

However, important questions regarding the genetic architecture of PKP2 cardiomyopathy remain. First, although its major associated phenotype is ARVC, pathogenic and likely pathogenic (P/LP) variants in PKP2 have also been associated with ventricular arrhythmia and sudden cardiac death without overt...
MATERIALS AND METHODS

Discovery data set
Clinical genetic testing cohorts. We mined free text and ICD-10 codes from 11,132 individual de-identified genetic tests from Invitae, Inc. for probands with ACM-associated diagnoses who were sequenced for PKP2. As there is no universally accepted disease definition of ACM, we defined ACM probands as those carrying a diagnosis of cardiomyopathy, ventricular arrhythmia, or sudden cardiac death (Supplementary Table 1). We identified 4,941 probands carrying ACM-associated diagnoses (“ACM Genetic Testing Cohort,” Fig. 1). Of these, 980 carried a specific diagnosis of ARVC (“ARVC Genetic Testing Cohort,” Fig. 1), though it was not possible to determine from available data whether these probands met 2010 Task Force Diagnostic Criteria. In this discovery data set, all detected variants were included, regardless of pathogenicity adjudication, to allow for agnostic evaluation of disease association. Stop-gain and frameshift variants were included in the truncating variant group, and only nonsynonymous missense variants were included. Splice site variants were not included given unknown transcript consequences of most variants in predicted splice sites. Only probands carrying variants sufficiently rare to cause disease were included (minor allele frequency [MAF] ≤ 0.0001). The validation data set, patients with a definite diagnosis of ARVC (Johns Hopkins [JHU] and Netherlands cohorts) were included and those with a pathogenic or likely pathogenic variant in PKP2 were compared to individuals in the Geisinger MyCode cohort with PKP2 variants but without ACM-related diagnoses.

Genome Aggregation Database (gnomAD) Population Genomics Cohort. Individuals carrying nonsynonymous missense and truncating variants in PKP2 from 123,136 exomes and 15,496 genomes in the Genome Aggregation Database (gnomAD V2.1.1) were collated. On average, sequencing from 70,728 individuals passed quality control at each coding position of the PKP2 transcript, and we defined this as the size of the general population sequenced. For purposes of calculating the EF of truncating and missense variants for ARVC and ACM, only individuals carrying variants with gnomAD MAF ≤ 0.0001 were included to avoid counting compound heterozygotes or variants in cis as more than one individual. One thousand seven hundred sixty-eight individuals carrying RV involvement. The EF of ACM explained by PKP2 variants that is inclusive of these phenotypes remains to be investigated. Second, though P/LP PKP2 missense variants have been reported and validated with functional studies, their overall impact in ACM and specifically ARVC at a population level is difficult to discern. A regional assessment for disease enrichment of PKP2 missense and truncating variants may help to inform variant pathogenicity assessment. We investigated these questions in a multicohort study inclusive of a large database of clinical genetic testing, a rigorously phenotyped cohort of patients with definite ARVC, the population genomics database gnomAD, and the Geisinger MyCode cohort, which is a population cohort with available clinical impact in ACM and specifically ARVC at a population level is difficult to discern. A regional assessment for disease enrichment of PKP2 missense and truncating variants may help to inform variant pathogenicity assessment.

Resultant pools of individuals were formed for ACM-associated truncating variant probands (N = 98, solid red box, Fig. 2) and ACM-associated missense variant probands (N = 40, solid blue box Fig. 2). LMM genetic tests were not included in EF assessment because the total number of ACM probands tested at LMM was not obtained.

Genetics in Medicine (2021) 23:1961 – 1968
PKP2 missense and 97 carrying PKP2 truncating variants were identified in gnomAD (light gray boxes, Fig. 1). For regional analyses, differential MAF restrictions were used to optimize the heuristic (see Supplementary Methods).

Validation data set
To complement the discovery data set described above, we compiled rigorously phenotyped data sets for validation analyses. These provide more precise estimation of the odds of ARVC association with specific variant classes and locations based both on inclusion of only definite ARVC in the disease cohort as well as excluding ACM-relevant phenotypes from the control cohort (Geisinger MyCode).

Definite ARVC Cohort. We assembled a large group of probands with definite ARVC.26 This cohort is comprised of two contributing groups: Johns Hopkins University (JHU)/Netherlands (NL) ACM Registries: The Johns Hopkins (JHU) ARVC Registry (arvc.com) and Netherlands ACM Registry (acmregistry.nl) both prospectively enroll individuals with ACM, most typically ARVC, as well as individuals who are at risk for these conditions based on genotype and clinical features.22 PKP2-variant-carrying probands from the JHU/NL registries were drawn from a recent study that characterized P/LP desmosomal variants among patients who met de novo criteria based on annotations from Ensembl VEP. We excluded all individuals with closer than 3rd degree relatedness based on the exclusive focus on probands within the clinical cohorts. Finally, to improve specificity in this control population, patients with diagnoses of “other/unsupported” cardiomyopathy, ventricular arrhythmia/tachycardia/fibrillation, bundle branch block, or cardiac arrest were excluded (N = 4721, Figs. 1 and 2; See Supplementary Table 1 for specific ICD-10 codes), leaving 80,361 individuals in the final analyses.

International ARVC Missense Variant Cohort. Given the rarity of P/LP missense variants in PKP2, in addition to probands with missense variants from the NL and JHU Registries we also included data from multiple international ARVC centers of excellence in Europe, the United States, and Australia (Zurich ARVC Program, Arrhythmogenic Cardiomyopathy program at the University College London Institute of Cardiovascular Science, Stanford Center for Inherited Cardiovascular Disease, The Australian Genetic Heart Disease Registry, The Familial Cardiomyopathy Registry [University of Colorado–University of trieste, Italy]) to assemble a cohort of probands with definite ARVC per 2010 Task Force Criteria with similarly rare PKP2 missense variants (MAF ≤ 3.6 × 10⁻⁵). Window size was determined based on the following parameters: desired power 0.80, alpha error 0.01, detectable odds ratio 4.5 using the calculator available at http://openepi.com/Power/PowerCC.htm (Supplementary Table 3). We then compared the fraction of individuals within each of these windows (number of individuals with variants falling in a window/number of total individuals in respective database) between the ACM genetic testing cohort and gnomAD individuals, calculating an odds ratio for enrichment of ACM probands versus gnomAD individuals (and again for Definite ARVC probands versus MyCode participants). Sliding windows were then shifted.
by a single base pair down the length of the coding transcript to increase the granularity of identification of regional enrichment. More detail regarding the progressive development of the heuristic is included in the Supplementary Methods, Supplementary Fig. 1, and Supplementary Table 4.

Statistical analyses

For comparison of proportions with \( n < 100 \), a Fisher exact test was performed, otherwise a Chi-squared test was used. EF was calculated as a function of the odds ratio (OR): EF = (OR − 1)/OR. Correction for multiple testing was performed using a Benjamini–Hochberg method with false discovery rate (FDR) of 0.01 (or 0.05 for validation). All analyses were performed using Stata 14 or R. Bespoke code written for these analyses is available upon request.

RESULTS

PKP2 truncating variants explain a significant etiologic fraction of ACM, most specifically ARVC

The OR for association of each PKP2 variant type (truncating or missense) with an ARVC diagnosis in the Invitae cohort was calculated (\( N = 980 \), Fig. 1). Truncating variants were highly enriched in probands with an ARVC diagnosis as compared to gnomAD (Table 1). Rare PKP2 missense variants were less likely to be identified in the ARVC genetic testing cohort than in gnomAD. Next, this result was assessed in the validation database (JHU/Netherlands ARVC Registries and MyCode), addressing the hypothesis that high fidelity clinical phenotyping of these cases and elimination of affected individuals in the general population would more precisely measure the effect. As suspected, this yielded a significantly higher odds of disease association and EF (OR 5.5 [0.8, 31]; EF 0.69 [0.44, 0.81]; \( p = 9.1 \times 10^{-5} \)). Of note, these may yet be slight underestimates of the actual EF of PKP2 variants in ACM, as only ICD-10 codes found in disease cohorts were excluded (Supplementary Table 1), and therefore the MyCode population may still include some individuals with more generalized cardiac diagnoses.

To investigate whether the inclusion of probands with any ACM-associated phenotype (not only ARVC) was adequate to detect an effect of PKP2 truncating variants in ACM, we performed the same analysis using data from the ACM genetic testing cohort (Supplementary Table 1 inclusive of, but not exclusive to ARVC; Fig. 1, \( N = 4,941 \)). Of these probands, 47 had truncating variants in PKP2, yielding a modest enrichment for disease association of truncating variants compared to gnomAD (OR 6.9 [4.9, 9.8]; EF 0.85 [0.80, 0.88]; \( p < 0.0001 \)). The large decrease in effect size for ACM versus ARVC specifically highlights the specificity of PKP2 truncating variants for an ARVC phenotype, a finding that has been reported in smaller cohorts.12

Regions of PKP2 enriched for ACM-associated missense variation include known functional domains and the previously unrecognized C-terminus

We went on to examine potential regional enrichment for disease associated missense and truncating variation in PKP2. Using progressively restrictive inclusion of population variants and sliding window size based on statistical power calculations, we developed a heuristic for regional evaluation of disease proband enrichment compared to population control cohorts (additional detail in Supplementary Methods). Initial examination of regional distribution of missense variants in the discovery data set identified several disease-enriched windows along the PKP2 transcript (Fig. 3a). These capture not only most Armadillo repeats, but also the previously reported HR2 domain. Additionally, the PKP2 C-terminus was also highly enriched across different conditions of sliding window size and MAF restriction (Supplementary Figure 1).

Given the specificity of PKP2 cardiomyopathy for the ARVC phenotype in particular, we hypothesized that of the ACM probands and PKP2 missense variants in the Clinical Genetic Testing Cohort (\( N = 40 \), Fig. 2, solid blue box), those with ARVC-specific diagnosis would be enriched in predicted windows (\( N = 16 \)). We found that ARVC probands were marginally enriched in predicted windows over those with other ACM-related diagnoses (OR 5 [0.8, 3.6], \( p = 0.048 \)). Interestingly, this did not hold true when regions identified with lenient or strict gnomAD MAF restrictions were examined (Supplementary Figure 1, MAF ≤ 0.01: OR 1.4 [0.17, 17.4], \( p = 0.7 \); MAF ≤ 3.6 \times 10^{-5} : OR 1.9 [0.41, 8.6], \( p = 0.34 \)).

Regions of PKP2 enriched for ACM-associated missense variation in the discovery cohort are also enriched for pathogenic and likely pathogenic variant ARVC patients

To validate these findings further, we performed a regional analysis using the same window size and MAF restrictions in the validation data set (Fig. 3b). A well-described pathogenic founder missense variant, c.2386T>C (p.C796R), was overrepresented in these definite ARVC probands. For this reason, only this region of the transcript met statistical significance at FDR 0.01. However, the odds of disease association in this analysis do reproduce several Armadillo repeats and also display a peak near the HR2 domain, overlapping with many of the enriched windows identified in the discovery data set analysis.

---

**Table 1.** Truncating variants in PKP2 are more strongly associated with ACM phenotypes than missense variants.

| Disease groupa | \( n \) (%) | gnomADb | \( N = 70,728 \) \( n \) (%) | OR (95% CI) | EF (95% CI) | \( p \) value |
|----------------|------------|---------|-----------------------------|-------------|-------------|-----------|
| **Genetic testing ACM (\( N = 4941 \))** | | | | | | |
| Truncating | 47 (0.9%) | 98 (0.1%) | 6.9 [4.9, 9.8] | 0.85 [0.8, 0.9] | \( < 2 \times 10^{-16} \) |
| Missense | 137 (2.8%) | 1768 (2.2%) | 1.1 [0.9, 1.3] | 0.09 [0.0, 0.2] | 0.23 |
| **Genetic testing ARVC (\( N = 980 \))** | | | | | | |
| Truncating | 35 (3.5%) | 98 (0.1%) | 26.7 [18.1, 39.5] | 0.96 [0.94, 0.97] | \( < 2 \times 10^{-16} \) |
| Missense | 13 (1.3%) | 1768 (2.2%) | 0.5 [0.3, 0.9] | | 0.02 |
| **Definite ARVC (\( N = 472 \))** | \( n \) (%) | MyCodeb, | \( N = 80,361 \) \( n \) (%) | OR (95% CI) | EF (95% CI) | \( p \) value |
| Truncating | 170 (36%) | 34 (0.04%) | 853 [581, 1251] | 1.00 [1.00, 1.00] | \( < 2 \times 10^{-16} \) |
| Missense | 16 (3.4%) | 846 (1.1%) | 3.19 [1.85, 5.63] | 0.69 [0.44, 0.81] | 9.1 \times 10^{-5} |

ACM arrhythmogenic cardiomyopathy, ARVC arrhythmogenic right ventricular cardiomyopathy, CI confidence interval, EF etiologic fraction, OR odds ratio.

*Probands, ACM-associated or ARVC specific diagnosis by ICD-10 or requisition (Invitae, Inc.), MAF ≤ 0.0001.

**Minor allele frequency (MAF) ≤ 0.0001, Relatives closer than 3rd degree and individuals with ACM-relevant diagnoses removed from MyCode.**
Of note, the significant peak around the c.2386T>C variant observed in the validation cohort was not observed in the discovery cohort. We further investigated this finding in the discovery cohort, and found that the regions within 33 bp of this variant were enriched for variation in gnomAD. We hypothesized that this was largely driven by a variant prevalent specifically in participants of African and Latino ancestry (MAF $7 \times 10^{-4}$, p.Thr798Ala). Given that the c.2386T>C founder variant, and indeed much of ARVC is described in individuals of non-Finnish European ancestry, we then performed this regional analysis including only individuals of non-Finnish European ancestry from gnomAD (MyCode participants are $>90\%$ European ancestry). Despite representation of the founder variant in the ACM genetic testing cohort, this did not significantly change our findings, and specifically did not identify the region around the founder variant as enriched for disease (likely due to 11 non-Finnish European individuals carrying c.2392A>G [p.Thr798Ala], Supplementary Figure 2). As the MyCode registry includes $93.5\%$ individuals of European ancestry, we did not repeat an ancestry-specific analysis in the validation data set (the ancestry admixture of each cohort is included in Supplementary Table 5).

Assessment of truncating variation identifies no regional disease enrichment
Regional association of truncating variation has previously illuminated functional motifs (e.g., internal promoters) in other genes. Therefore, we examined the distribution of variants across the transcript and found no linear association of transcript location with enrichment for ACM versus population associated truncating variation ($R^2 = 0.003$, $p = 0.42$).

We went on to perform a regional analysis for enrichment of ACM-associated truncation. Due to the very restricted sample size in gnomAD ($N = 97$), we used a 132-bp window for this analysis. We did not find any windows enriched for ACM-associated variation, consistent with the hypothesis that truncating variation is likely disease associated regardless of its location (Fig. 4a, b). Because there was a notable increase in the OR of windows around the HR2 domain, we repeated this analysis with 33-bp windows to ensure enough precision with the sliding window size, and still found no significant enrichment. We did note a significant overrepresentation of truncating variation in the general population at positions c.926-c.1004, driven by 12 individuals each with p.Ala325TrpfsTer28 and p.Gln323ArgfsTer12 respectively. Based on publicly available data in gnomAD, it is not possible to determine whether these variants exist in independent individuals or are carried in a common haplotype. We examined these variants in MyCode and found that they were part of a common haplotype in 41 individuals that leads to the resolution of predicted truncation, instead causing two missense variants in tandem: p.Gln323_Ala324delinsArgLeu. These individuals in the MyCode cohort were recoded as having missense variants for all analyses.

Fig. 3 Regional assessment of missense variants in PKP2 identifies potential hotspots for pathogenic variation. (a) Arrhythmogenic cardiomyopathy (ACM) genetic testing cohort (blue, $N = 40$, minor allele frequency [MAF] $\leq 3.6 \times 10^{-5}$) vs. gnomAD (gray, $N = 3970$, MAF $\leq 0.001$) Odds of inclusion of disease associated variant. (b) International ARVC Missense Variant Cohort (striped blue, MAF $\leq 3.6 \times 10^{-5}$, $N = 26$) vs. Geisinger MyCode cohort (striped gray, $N = 1678$, MAF $\leq 0.001$). Light blue shading indicates regional disease enrichment, false discovery rate (FDR) $= 0.01$. ARVC arrhythmogenic right ventricular cardiomyopathy.
Here, we employ clinical genetic testing cohorts, highly phenotyped definite ARVC cohorts, and population genomic data with and without associated clinical information to describe the genetic architecture of \textit{PKP2} cardiomyopathy. We show that truncating variation at any position along the \textit{PKP2} transcript explains a large EF of ARVC, and highlight missense variation at the C-terminus of the \textit{PKP2} transcript encoding a potential unrecognized functional domain. We find that the magnitude of variant disease contribution is most accurately measured with highly specific disease phenotypes and that elimination of disease-associated individuals from control populations increases this specificity. Lastly, we develop a balanced heuristic for the regional comparison of human disease and population-associated genetics to illuminate potential functional protein domains associated with disease. These findings have direct clinical implications. Regional mapping of novel \textit{PKP2} variants to areas of the gene enriched for disease association in this study may aid in variant interpretation. In combination with this, the knowledge that truncating variants are very likely disease causing and particularly for ARVC will aid in the diagnosis and care of patients with \textit{PKP2} cardiomyopathy and their families.

\textbf{DISCUSSION}

We show, in two independent data sets, that \textit{PKP2} truncating variants explain a large EF of ARVC, and that there is no relationship between their transcript position and their likelihood of disease association. These findings reinforce prior evidence that \textit{PKP2} truncating variation explains the largest EF of ARVC in an independent, highly phenotyped population.\textsuperscript{1} Our findings also demonstrate that with exclusion of patients carrying disease-relevant phenotypes from the control population in MyCode and high-fidelity clinical phenotyping for definite ARVC, the true EF of \textit{PKP2} truncating variants is higher than predicted by our less well phenotyped clinical genetic testing cohort. However, these findings also indicate that discovery can detect these effects using larger but less clinically defined databases, though the effect size of such associations is likely to be underestimated. To date, our knowledge of the spectrum of disease caused by the variants we identify has been limited by our approach, which tests only those patients fitting a specific and often rigidly defined clinical phenotype. As we move into an era of genome-first approaches to diagnosis, we may find that where the specificity of a given genotype for a particular clinical phenotype is high, its population penetrance remains small.\textsuperscript{20} It is possible that other relevant phenotypes exist in patients carrying these pathogenic alleles.
(e.g., sudden cardiac arrest in the absence of diagnostic ARVC imaging criteria), and contribute to that gap in penetrance of the expected clinical phenotype. Inclusion of broader disease definitions in our study of rare disease may be useful to illuminate some of these gaps.

Human genetics illuminates known and potential functional domains in PKP2. Our regional analysis identifies potential hotspots for missense variation in most of the Armadillo repeats of PKP2, helical structures that were first described in the β-catenin crystal structure and are thought to facilitate protein–protein interactions with acidic substrates. We again implicate the HR2 domain, critical for desmosomal assembly. That this regional analysis did not identify the region surrounding the functionally validated PKP2 founder variant c.2386T>C; p.C796R in the discovery cohort, but was able to detect it in the validation cohort, requires consideration. This may indicate that the p.C796 position is itself critical to protein structure (instability of PKP2 p.C796R has been reported) but that it does not otherwise lie in a functional domain encompassing more than this residue. It may also indicate that exclusion of relevant diagnoses in the population made possible in the MyCode cohort is necessary for detection of this regional pathogenicity. The overrepresentation of this variant in the definite ARVC cohort due to founder effect also likely drives this finding, as the ACM genetic testing cohort has a more diverse ancestry admixture (Supplementary Fig. 2, legend). Finally, the exclusion of non-ARVC phenotypes from the validation cohort may result in more ARVC-specific regional enrichment, whereas the discovery cohort may include variants that might be more associated with early arrhythmia or ALVC phenotypes.

In addition, our analysis illuminates the C-terminus as a potential functional domain. This implies that both the N- and C-termini of the PKP2 protein are functionally critical. That disease-associated truncating variants are not enriched nearer the N-terminus, but rather distributed throughout may also support this conclusion. Although C-terminus enrichment was not recapitulated in the validation data set, this is to be expected given the restriction of the validation cohort to P/LP variants, and the previously unrecognized significance of this region. At present, molecular investigation of the PKP2 C-terminus has been limited, and specific knowledge of its protein domains, especially in the cardiomyocyte, is lacking. In the PKP2 homologue Plakophilin 1, the C-terminus is necessary for desmosome assembly in epithelial cells. Therefore, missense variants in this region of PKP2 may be more functionally consequential in ACM than previously thought. Given its centrality in the desmosome, interactors of PKP2 may require the C-terminus. Further investigation of these molecular interactions will illuminate not only our understanding of disease mechanisms, but also will serve to reinforce missense variant interpretation.

Limitations
As with any study in rare disease, our findings are limited by the small sample size available to study granular hypotheses. We have described above the measures taken to avoid selection bias and other bias associated with studying rare disease. Though we have performed sensitivity analyses to ensure that our novel findings are not related to differential ancestry mix between cases and controls, the effect of ancestry on variant effect remains difficult to study in existing biobanks and patient populations with limited admixture. Therefore our findings may be less applicable in patients of non-European ancestry. It is important to note that while this analysis offers a regional assessment of variant-to-disease association and therefore highlights the power of human genetics to illuminate protein structure and function, it may supplement but not replace significant requisite data in the adjudication of individual variant pathogenicity as outlined by the American College of Medical Genetics and Genomics.

CONCLUSION
We use human genetics to illuminate detailed gene-wide and region-specific variant–disease association in PKP2 cardiomyopathy. As we move toward a genome-first era of medicine, the development and broad application of the methods presented here can provide a platform for the incorporation of human genetics into the position-specific evaluation of variant pathogenicity at scale. As such, the analysis presented here seeks to improve diagnosis and understanding of disease mechanisms by linking genetic discovery directly to clinical observations.

DATA AVAILABILITY
All data have been made available in de-identified form in the included supplementary files. Any additional queries can be directed to the corresponding authors.

Received: 8 February 2021; Revised: 16 May 2021; Accepted: 17 May 2021; Published online: 12 June 2021

REFERENCES
1. Walsh, R. et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med. 19, 192–203 (2017).
2. Whiffin, N. et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet. Med. 19, 1151–1158 (2017).
3. Deo, R. C. Alternative splicing, internal promoter, nonsense-mediated decay, or all three: explaining the Distribution of truncation variants in titin. Circ. Cardiovasc. Genet. 9, 419–425 (2016).
4. Homburger, J. R. et al. Early and late onset HCM causing mutations in MYH7 Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation. Proc. Natl. Acad. Sci. USA 113, 6701–6706 (2016).
5. Smith, E. D. et al. Desmoplakin cardiomyopathy, a fibrillar and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation. 141, 1872–1884 (2020).
6. Helms, A. S. et al. Spatial and functional distribution of MYBPC3 pathogenic variants and clinical outcomes in patients with hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. https://doi.org/10.1161/CIRCGEN.120.002929 (2020).
7. Grondin, S. et al. Missense variants in the spectrin repeat domain of DSP are associated with arhythmogenic cardiomyopathy: a family report and systematic review. Am. J. Med. Genet. A 182, 2359–2368 (2020).
8. Parikh, V. N. et al. Regional variation in RBM20 causes a highly penetrant arrhythmogenic cardiomyopathy. Circ. Heart Fail. 12, e005371 (2019).
9. Chen, S. N. et al. The hippo pathway is activated and is a causal mechanism for sudden unexplained cardiac death events. Circ. Genom. Precis. Med. https://doi.org/10.1161/CIRCGEN.120.003273 (2021).
10. Chen, X., Bonné, S., Hatzfeld, M., van Roy, F. & Green, K. J. Protein binding and functional characterization of Plakophilin 2: a platform for the incorporation of human genetics into the position-specific evaluation of variant pathogenicity at scale. Circ. Cardiovasc. Genet. 9, 419–425 (2016).
11. Ingles, J. et al. Concealed arrhythmogenic right ventricular cardiomyopathy in sudden unexplained cardiac death events. Circ. Genom. Precis. Med. 11, e003355 (2018).
12. Bhonsale, A. et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardio-myopathy-associated mutation carriers. Eur. Heart J. 36, 847–855 (2015).
13. Xu, T. et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J. Am. Coll. Cardiol. 59, 542–549 (2020).
14. Novelli, V., Malkani, K. & Cerrone, M. Pleiotropic phenotypes associated with PKP2 variants. Front. Cardiovasc. Med. 5, 184 (2018).
15. Lahtinen, A. M. et al. Plakophilin-2 missense mutations in arrhythmogenic right ventricular cardiomyopathy. Int. J. Cardiol. 126, 92–100 (2008).
1968

18. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
19. Carey, D. J. et al. The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet. Med. 18, 906–913 (2016).
20. Marcus, F. L. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur. Heart J. 31, 806–814 (2010).
21. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
22. te Riele, A.S.J.M. Bosman, L.P., Cadrin-Tourigny, J. & James, C. A. Arrhythmogenic right ventricular cardiomyopathy: Better together. Current Concepts in Arrhythmogenic Cardiomyopathy, second edition Minneapolis, USA.
23. van Lint, F. H. M. et al. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants are Rarely De Novo. Circ Genom Precis Med. 12, e002467 (2019).
24. Staples, J. et al. Profiling and Leveraging Relatedness in a Precision Medicine Cohort of 92,455 Exomes. Am. J. Hum. Genet 102, 874–889 (2018).
25. Dewey, F. E. et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovER study. Science. 354, aaw6141 (2016).
26. Haggerty, C. M. et al. Electronic health record phenotype in subjects with genetic variants associated with arrhythmogenic right ventricular cardiomyopathy: a study of 30,716 subjects with exome sequencing. Genet. Med. 19, 1245–1252 (2017).
27. Huber, A. H., Nelson, W. J. & Weiss, W. I. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell 90, 871–882 (1997).
28. Kirchner, F. et al. Molecular insights into arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 missense mutations. Circ. Cardiovasc. Genet. 5, 400–411 (2012).
29. Sobolik-Delmaire, T., Katafias, D. & Wahl, J. K. 3rd Carboxyl terminus of Plakophilin-1 recruits it to plasma membrane, whereas amino terminus recruits desmoplakin and promotes desmosome assembly. J. Biol. Chem. 281, 16962–16970 (2006).
30. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–423 (2015).

ACKNOWLEDGEMENTS

This work was supported by the Boring Trust Research Award (A.M.D.), NHLBI K08 HL143185 (V.N.P.), the John Taylor Babbitt Foundation (V.N.P.), the Samoff Cardiovascular Research Foundation (V.N.P.), Netherlands Organisation for Scientific Research (NWO) 040.11.586 (C.A.J.), NHLBI R01 HL141901 (C.M.H., C.A.J., M.A.K.), National Health and Medical Research Council Career Development Fellowship 1162929 (J.A.), National Health and Medical Research Council (NHMRC) Practitioner Fellowship #1154992 (C.S.), a New South Wales Health Cardiovascular Disease Clinician Scientist Grant (C.S.) Foundation Leducq Transatlantic Networks of Excellence Program grant number 14CVD03 (P.S., L.M., G.S.), the National Institute for Health Research University College London Hospitals Biomedical Research Centre, UK (P.S. and P.S.) and Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (C.VON0015-12 eDetect 2018-30 PREDICT2 (J.P.V.T.). The Familial Cardiomyopathy Registry was supported by NHLBI R01 HL69071, R01 HL16906, R01 HL147064, NIH/NCATS Colorado CTSA UL1 TR001082 (L.M.); UM1 HG006542, R01 HL109290 (M.G.T.); CRFRIende Foundation and Cassa di Risparmio di Gorizia Foundation (G.S.). The Johns Hopkins ARVC/D Program is supported by the Leonie-Wild Foundation, the Leyla Erkan Family Fund for ARVD/Research, the Dr. Francis P. Chiramonte Private Foundation, the Dr. Satish, Rupali, and Robin Shah ARVD Fund, at Johns Hopkins, the Bogle Foundation, the Healing Hearts Foundation, the Campanella family, the Patrick J. Harrison Family, the Peter French Memorial Foundation, and the Wilfendiner Endowments.The Zurich ARVC Program is supported by the Georg und Bertha Schwyzer-Winiker Foundation, Baugarten Foundation, Wild Foundation, Swiss National Science Foundation (SNF), and the Swiss Heart Foundation. Laurens P. Bosman is acknowledged for his help in collecting clinical data. C.B., K.P., R.C., and B.B. are supported by Regional Endowments. The Zurich ARVC Program is supported by the Georg und Bertha Schwyzer-Winiker Foundation, Baugarten Foundation, Wild Foundation, Swiss National Science Foundation (SNF), and the Swiss Heart Foundation. Laurens P. Bosman is acknowledged for his help in collecting clinical data. C.B., K.P., R.C., and B.B. are supported by Regional

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41436-021-01233-7.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021, corrected publication 2021

V.N.P.: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing—review & editing; C.M.H.: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing—review & editing; A.M.D.: Data curation, Formal analysis, Funding acquisition, Project administration, Validation, Visualization, Writing—initial manuscript; A.K.: Data curation, Formal analysis; C.M.R.: Data curation, Writing—review & editing; J.G.: Data curation, Formal analysis; H.Z.: Data curation; M.H.: Data curation; B.M.: Data curation; C.T.: Data curation; K.P.: Data curation, Writing—review & editing; A.P.: Data curation, Writing—review & editing; A.M.-D.: Data curation; M.A.K.: Formal analysis; A.B.: MD Data Curation; J.J.: Writing—review & editing: C.S.: Writing—review & editing; B.B.: Data curation; R.C.: Data curation; C.B.: Data curation; J.D.H.J.: Data curation, Writing—review & editing; R.N.: Data curation, Writing—review & editing; B.F.: Data curation, Writing—review & editing; M.C.: Writing—review & editing; L.M.: Data curation, Writing—review & editing, Funding acquisition; M.R.G.T.: Data curation, Writing—review & editing, Funding acquisition; G.S.: Data curation, Writing—review & editing, Funding acquisition; M.M.: Data curation, Writing—review & editing, Funding acquisition; A.S.: Data curation, Writing—review & editing, Funding acquisition; P.E.: Data curation, Writing—review & editing, Funding acquisition; P.S.: Data curation, Writing—review & editing. Funding acquisition; Regeneron Genetics Center Data: curation, Writing—review & editing, Funding acquisition.

ETHICS DECLARATION

This research was approved by the Stanford University School of Medicine Institutional Review Board (IRB). All institutions involved in human participant research also received local IRB approval. As no identifying personal health information was collected in the discovery data sets, consent was not required. Consent was obtained from subjects in the validation data sets per respective IRB requirements.

COMPETING INTERESTS

R.L.N. is an employee and stockholder in Invitae, a consultant for Pfizer Pharmaceuticals, and consultant and stock holder for Maze Therapeutics and Genome Medical. B.M. is a consultant for MyGeneCounsel. A.B. is an employee of Regeneron Genetics Center. A.M.S. received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic, and speaker fees from Bayer Healthcare and BMS/Pfizer. The other authors declare no competing interests.